A new guideline from KDIGO on IgA Nephropathy is being reported, with some outlets describing it as paradigm-shifting. The guideline appears to focus on targeted therapies and mechanism-driven treatment approaches. Reports also suggest that the guideline may lead to more personalized care and a redefinition of treatment goals for the disease.